Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
=== Semi-automated system === Blood volumes can also been measured in humans using the non-radioactive, carbon monoxide (CO) rebreathing technique. With this technique, a small volume of pure CO gas is inhaled and rebreathed for a few minutes. During rebreathing, CO binds to hemoglobin present in red blood cells. Based on the increase in blood CO after the rebreathing period, the volume of blood can be determined through the dilution principle.
== Increasing stability of peptide drugs == Many strategies have been employed to increase the stability of peptide drugs, because although they have so many desirable characteristics, they are short lived in the body as a result of rapid degradation and clearance. With half-lives of some peptides and proteins only being a few minutes, they are very ineffective in drug delivery. Mechanisms involved in their clearance include peripheral blood mediated elimination by proteolysis, renal and hepatic elimination, and also receptor-mediated endocytosis. One of the main reasons for such rapid clearance is molecular weight. Molecules that have a low molecular weight (40-50 kDa) are rapidly cleared by renal filtration via the glomerular filtration barrier (GBM) into the urine. As a result of this, increasing the size of a peptide drug is a good starting point to improve half-life. Peptide modifications to extend half-life include PEGylation, glycosylation, cyclization, serum albumin binding, and lipidation. PEGylation is the attachment of polyethylene glycol (PEG) chains to the peptide via covalent bonds, helping to increase molecular weight, and limit enzymatic degradation as a result of steric hindrance caused by adding the PEG. PEGylation offers a number of benefits for pharmaceutical applications such as improved water solubility, high mobility in solution, as well as low toxicity and low immunogenicity. This does however depend on the molecular weight of the attached PEG.
==== Preventive measures ==== In August 2010, Purdue Pharma reformulated their long-acting oxycodone line, marketed as OxyContin, using a polymer, Intac, to make the pills more difficult to crush or dissolve in water to reduce non-medical use of OxyContin. Inactive ingredients/excipients are butylated hydroxytoluene (BHT), hypromellose, polyethylene glycol 400, polyethylene oxide, magnesium stearate, and titanium dioxide. The FDA approved relabeling the reformulated version as abuse-resistant in April 2013. Pfizer manufactures a preparation of short-acting oxycodone, marketed as Oxecta, which contains inactive ingredients, referred to as tamper-resistant Aversion Technology. Approved by the FDA in the U.S. in June 2011, the new formulation, while not being able to deter oral recreational use, makes crushing, chewing, snorting, or injecting the opioid impractical because of a change in its chemical properties.
Christianity is the country's predominant faith, with Catholicism being its largest denomination. Brazil has the world's largest Catholic population. According to the 2022 demographic census (the PNAD survey does not inquire about religion), 56.75% of the population followed Catholicism; 26.85% Protestantism; 1.84% Kardecist spiritism; 5.06% other religions, undeclared or undetermined; while 9.28% had no religion. Religious diversity in Brazil developed from the meeting of the Catholic Church with the religious traditions of enslaved African peoples and indigenous peoples. This confluence of faiths during the Portuguese colonization of Brazil led to the development of a diverse array of syncretistic practices within the overarching umbrella of Brazilian Catholic Church, characterized by traditional Portuguese festivities. Religious pluralism increased during the 20th century, and the Protestant community had grown to include over 22% of the population by 2010—partly due to a mixture of American missionary and US government influence. The most common Protestant denominations are Evangelical Pentecostal ones. Other Protestant branches with a notable presence in the country include the Baptists, Seventh-day Adventists, Lutherans and the Reformed tradition. In recent decades, Protestantism, particularly in forms of Pentecostalism and Evangelicalism, has spread in Brazil, while the proportion of Catholics had dropped significantly during the 2010s.
Sources: en.wikipedia.org
Sanders' Original Recipe of "11 herbs and spices" is one of the best known trade secrets in the catering industry. The recipe is not patented, because patent law requires public disclosure of an invention and provides protection only for a strictly limited term, whereas trade secrets can remain the intellectual property of their holders in perpetuity. A copy of the recipe, signed by Sanders, is held inside a safe inside a vault in KFC's Louisville headquarters, along with 11 vials containing the herbs and spices. To maintain the secrecy of the recipe, half of it is produced by Griffith Laboratories before it is given to McCormick, who add the second half. In 1999, a couple who bought the house formerly occupied by Colonel Sanders found scribbled notes purported to be the secret recipe. Initially, KFC wanted to file a lawsuit against the couple to stop an auction of the notes but, by early 2001, it dropped the lawsuit, claiming the scribbled notes are "nowhere close" to the original recipe. Joe Ledington of Kentucky, a nephew by marriage of Colonel Sanders, claimed to have found a copy of the original KFC fried chicken recipe on a handwritten piece of paper in an envelope in a scrapbook. In August 2016, Chicago Tribune staffers conducted a cooking test of this recipe and claimed after a few attempts that, with the addition of the MSG flavor-enhancer Ac'cent, they produced fried chicken which tasted "indistinguishable" from the chicken they purchased at KFC.
Hematopathology or hemopathology (both also spelled haem-, see spelling differences) is the study of diseases and disorders affecting and found in blood cells, their production, and any organs and tissues involved in hematopoiesis, such as bone marrow, the spleen, and the thymus. Diagnoses and treatment of diseases such as leukemia and lymphoma often deal with hematopathology; techniques and technologies include flow cytometry studies and immunohistochemistry. In the United States, hematopathology is a board-certified subspecialty by the American Board of Pathology. Board-eligible or board-certified hematopathologists are usually pathology residents (anatomic, clinical, or combined) who have completed hematopathology fellowship training after their pathology residency. The hematopathology fellowship lasts either one or two years. A physician who practices hematopathology is called a hematopathologist.
== History == The chemical elements came into being in two phases. The first commenced shortly after the Big Bang. From ten seconds to 20 minutes after the beginning of the universe the earliest condensation of light atoms was responsible for the manufacture of the four lightest elements. The vast majority of this primordial production consisted of the three lightest isotopes of hydrogen—protium, deuterium and tritium—and two of the nine known isotopes of helium—helium-3 and helium-4. Trace amounts of lithium-7 and beryllium-7 were likely also produced. So far as is known, all heavier elements came into being starting around 100 million years later, in a second phase of nucleosynthesis that commenced with the birth of the first stars. The nuclear furnaces that power stellar evolution were necessary to create large quantities of all elements heavier than helium, and the r- and s-processes of neutron capture that occur in stellar cores are thought to have created all such elements up to iron and nickel (atomic numbers 26 and 28). The extreme conditions that attend supernovae explosions are capable of creating the elements between oxygen and rubidium (i.e., atomic numbers 8 through 37). The creation of heavier elements, including those without stable isotopes—all elements with atomic numbers greater than lead's, 82—appears to rely on r-process nucleosynthesis operating amid the immense concentrations of free neutrons released during neutron star mergers.
== Regulation == The GnRHR responds to GnRH as well as to synthetic GnRH agonists. Agonists stimulate the receptor, however prolonged exposure leads to a downregulation effect resulting in hypogonadism, an effect that is often medically utilized. GnRH antagonists block the receptor and inhibit gonadotropin release. GnRHRs are further regulated by the presence of sex hormones as well as activin and inhibin.
=== RLM designations === Focke-Wulf Fw 40 short-range reconnaissance parasol monoplane (prototype), 1932; known internally as A 40. Focke-Wulf Fw 43 Falke (Falcon) – utility aircraft (prototype), 1932; known internally as A 43. Focke-Wulf Fw 44 Stieglitz (Goldfinch) – trainer (biplane), 1932. Focke-Wulf Fw 47 Höhengeier (Vulture) – weather aircraft, 1931; known internally as A 47. Focke-Wulf Fw 55 – biplane floatplane derived from the Albatros L102, 1932. Focke-Wulf Fw 56 Stösser (Goshawk) – advanced trainer (parasol monoplane), 1933 Focke-Wulf Fw 57 – twin-engined heavy fighter-bomber (prototype), 1935. Focke-Wulf Fw 58 Weihe (Kite) – transport/photo reconnaissance/weather research aircraft, 1937. Focke-Wulf Fw 61 – helicopter (prototype), 1936. Focke-Wulf Fw 62 – ship-borne reconnaissance (biplane seaplane), 1937. Focke-Wulf Ta 152 – interceptor/fighter (derived from Fw 190), 1944. Focke-Wulf Ta 154 Moskito (Mosquito) – night-fighter with wood structure like its British namesake, 1943. Focke-Wulf Fw 159 – fighter (prototype only), 1935. Focke-Wulf Fw 186 – autogiro reconnaissance aircraft (prototype), 1937. Focke-Wulf Fw 187 Falke (Falcon) – twin-engined two-seat heavy day fighter ("Zerstörer"), 1936. Focke-Wulf Fw 189 Uhu (Eagle Owl) – twin-engined, three-seat army cooperation/tactical reconnaissance, 1938. Focke-Wulf Fw 190 Würger (Shrike/butcher-bird) – single-seat fighter/interceptor, 1939 Focke-Wulf Fw 191 – twin-engine Bomber B design competitor (prototype), 1942. Focke-Wulf Fw 200 Condor – four-engine airliner and maritime patrol-bomber, 1937.
Sources: en.wikipedia.org
=== 24-norursodeoxycholic acid === A recent scientific breakthrough for cholestasis that has allowed us to evaluate a new treatment option is that a hydrophilic environment and bicarbonate production protects hepatocytes from bile acid. The novel agent norUDCA (24-norursodeoxycholic acid) can be passively absorbed by cholangiocytes. This leads to bicarbonate production and an environment that is less toxic. Mouse models have found promising results with norUDCA with the drug showing antiproliferative and anti-inflammatory properties. A recent clinical trial found norUDCA had significant dose-dependent reductions for ALP levels. This makes norUDCA a viable possibility to look into as it clearly plays a significant role in the treatment of cholestasis.
=== Elected officials === Mayor: Matthew Gentry Clerk-Treasurer: Tonya Thayer City Council, District 1: Mike Kincaid City Council, District 2: Keith Campbell City Council, District 3: Sandra Jasionowski City Council, District 4: Dick Robertson City Council, District 5: John Copeland City Council, At Large: Sierra Messenger City Council, At Large: Robert Hawkins
== Side effects == Rarely, heart failure and stroke in association with use of methylephedrine have been reported. Methylephedrine shows reinforcing effects, a measure of addiction and misuse potential, in monkeys.
Agents of the Four Seasons (Japanese: 春夏秋冬代行者, Hepburn: Shunkashūtō Daikōsha) is a Japanese light novel series written by Kana Akatsuki (author of Violet Evergarden) and illustrated by Suoh. It began publication under ASCII Media Works' light novel imprint Dengeki Bunko in April 2021. A manga adaptation of the first part illustrated by Nappa Komatsuka began serialization in Hakusensha's shōjo manga magazine LaLa in July 2022. An anime television series adaptation of the first part produced by Wit Studio aired from March to June 2026.
Fundus of the eye The central portion of the retina on back or deepest part of the eye. Damage to the fundus, even if the rest of the eye is in good condition, will have severe problems. For instance reading may become impossible. Funduscopy A test to look at the back area of the eye to see if there is any damage to the vessels that bring blood to the retina. The doctor uses a device called an ophthalmoscope to check the eye. There is also a special type of camera which takes photos of the eye (with dilated pupils) to record retinal conditions for future comparison.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.